Late-Phase Research for Pharma and Biotechs
We help you plan early for long-term commercial success, helping you to mitigate risk and establish evidence.

With accelerated approvals and regulatory focus on risk management and mitigation strategies, the need has never been greater for healthcare companies to be diligent when it comes to late-phase or peri-approval research.
Kantar has more than 30 years of clinical research experience and can design a customised study to meet the needs of your product or research area. Our solutions enable you to adhere to risk management requirements, establish evidence for safety issues, and assess health outcomes and economics in various settings.
Featured solutions
Get comprehensive research and data to evaluate patient outcomes, treatment patterns, resource utilisation and costs.
Accurate and holistic analysis on the incidence, distribution, and control of diseases and factors relating to health.
Save time and improve evidence generation with linked clinical and patient-reported data.
Also within Health
-
Real-World Evidence
-
Data and Analytics
-
Commercial Planning
-
Specialist Consulting
-
Clinical Research & Medical Affairs